FARXIGA (DAPAGLIFLOZIN tablets) Patient Assistance Program
Don’t let the high cost of brand SGLT2 inhibitor disrupt your diabetes, heart failure, or chronic kidney disease care. We help eligible patients access Farxiga (dapagliflozin tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey.
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Farxiga (dapagliflozin) is FDA-approved to improve glycemic control in type 2 diabetes, reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced or preserved ejection fraction, reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. SGLT2 inhibitor — broad cardiorenal benefits beyond glucose lowering.
- Without assistance, brand Farxiga costs commonly run approximately $580–$750 per 30-day supply.
- Through AffordMyPrescriptions, qualifying patients can access Farxiga for a flat $69.95 per month.
- Farxiga is included in the first wave of Medicare Part D drug price negotiation under the Inflation Reduction Act — negotiated price effective 2026 will substantially reduce cost for Medicare beneficiaries. Other SGLT2 inhibitors: empagliflozin (Jardiance — also IRA negotiated), canagliflozin (Invokana), ertugliflozin (Steglatro), bexagliflozin (Brenzavvy — typically cheaper). Generic metformin remains first-line for T2DM (~$5–$10/month). Other diabetes lines: generic sulfonylureas, generic pioglitazone, DPP-4 inhibitors (Januvia going generic, Tradjenta), GLP-1 receptor agonists (semaglutide, dulaglutide, tirzepatide), basal insulins. For HF/CKD: standard guideline-directed medical therapy (GDMT) — ARNI (Entresto generic emerging), ACE inhibitors/ARBs (generic), beta-blockers (generic), MRAs (generic spironolactone, eplerenone; Kerendia for T2DM CKD).
What Is Farxiga Prescription Assistance Program?
The Farxiga Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Farxiga (used for type 2 diabetes, heart failure, and chronic kidney disease management) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, endocrinology, cardiology, or nephrology coordination, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing diabetes, heart failure, or kidney disease.
At AffordMyPrescriptions, our Patient Advocates handle the entire Farxiga PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your prescriber for required medical documentation, follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Farxiga SGLT2 inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Farxiga enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your diabetes and cardiorenal treatment.
Pharmacy Price Comparison
- Without assistance, Farxiga costs hundreds of dollars per month at retail pharmacies. Discount cards and pharmacy coupons offer some relief, but they don't come close to what a Patient Assistance Program provides if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Farxiga advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$720/mo | Save ~$650/mo |
| CVS Pharmacy | ~$750/mo | Save ~$680/mo |
| Walmart | ~$620/mo | Save ~$550/mo |
| Costco | ~$580/mo | Save ~$510/mo |
| Medicare negotiated (2026) | ~$295/mo | Save under IRA negotiation |
*Just a heads-up: retail prices are estimates based on public data and vary by pharmacy. Fortunately, Afford My Prescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication for you—independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Farxiga Prescription Program?
The Farxiga Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. SGLT2 inhibitors offer important cardiorenal benefits beyond glucose lowering — Brenzavvy and Mark Cuban Cost Plus offer substantially cheaper class options.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Farxiga:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
Coupon cards expire and require constant renewal
Still $580–$750 per month even with the best discount
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly from the manufacturer
- We manage all paperwork, refills, and renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Farxiga assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Farxiga Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Farxiga:
Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks renal glucose reabsorption, producing glucosuria and modest weight and blood pressure reduction. The SGLT2 class has demonstrated substantial cardiorenal benefits — reducing heart failure hospitalization, cardiovascular death, and CKD progression — independent of diabetes status in many trials. Farxiga is approved across T2DM, HFrEF, HFpEF, and CKD.
How it works:
Type 2 diabetes involves insulin resistance and progressive beta-cell dysfunction leading to hyperglycemia and complications including cardiovascular disease and kidney disease. Heart failure with reduced or preserved ejection fraction and chronic kidney disease share inflammatory and hemodynamic mechanisms with cardiometabolic disease.
Dapagliflozin selectively inhibits SGLT2 in the proximal renal tubule — reducing glucose reabsorption — producing glucosuria, modest weight loss, modest blood pressure reduction, and natriuresis. SGLT2 class benefits in heart failure and CKD appear to extend beyond glucose lowering — including reduced glomerular hyperfiltration, improved cardiac energetics, and natriuretic effects. The DAPA-HF, DAPA-CKD, DAPA-MI, and DELIVER trials established cardiorenal benefits across diverse populations.
Form and use:
Farxiga 5 mg or 10 mg tablets once daily, taken in the morning with or without food. Starting dose 10 mg daily for HF/CKD. T2DM: 5 mg once daily, may increase to 10 mg. Renal dose considerations apply; recent guidance supports use down to eGFR 25 for cardiorenal protection. Hold during acute illness (especially with poor oral intake) to reduce DKA risk. Hold 3–4 days before planned surgery.
Generic availability:
No US generic Farxiga yet. Other SGLT2 inhibitors: empagliflozin (Jardiance — strong CV/HF mortality data EMPA-REG/EMPEROR), canagliflozin (Invokana), ertugliflozin (Steglatro — weaker outcomes), bexagliflozin (Brenzavvy — typically lower-priced). Cheaper SGLT2 access: Mark Cuban Cost Plus carries some at discounted prices. Other T2DM lines: metformin (generic, foundational first-line), generic sulfonylureas (caution hypoglycemia), generic pioglitazone, DPP-4 inhibitors (Januvia going generic, Tradjenta), GLP-1 receptor agonists (semaglutide, dulaglutide, tirzepatide), basal insulins. For HF specifically: ARNI (Entresto — generic emerging), ACE inhibitors/ARBs (generic), beta-blockers (carvedilol, metoprolol succinate, bisoprolol — generic), MRAs (spironolactone, eplerenone — generic), Kerendia (finerenone) for T2DM CKD, Verquvo (vericiguat) for advanced HF, Procoralan/Corlanor (ivabradine) for select HF patients. For CKD: ACE/ARB foundational, finerenone (Kerendia) for T2DM CKD, potassium binders (patiromer, Lokelma) for hyperkalemia.
Warnings:
**Class concerns: euglycemic diabetic ketoacidosis (especially during illness, surgery, fasting, alcohol — hold sick days, stop 3–4 days pre-surgery), genital mycotic infections (yeast — counsel hygiene), urinary tract infections, Fournier’s gangrene (rare necrotizing fasciitis of perineum — severe), volume depletion and hypotension (caution with diuretics and elderly), AKI (especially with volume depletion), hyperkalemia (with K-sparing medications), bone fracture risk (canagliflozin specifically), urosepsis.** Not for T1DM. Initial small eGFR drop expected and reversible (hemodynamic). Long-term renoprotective and cardioprotective benefits in trials. Discuss DKA recognition and sick-day rules with patients.
FAQ (Frequently Asked Questions)
How much does Farxiga cost without insurance?
Brand Farxiga $580–$750 per month. Under the IRA Medicare drug price negotiation effective 2026, the negotiated maximum fair price is approximately $295 per month for Medicare beneficiaries. Brenzavvy (alternative SGLT2 inhibitor) costs about $50 per month — substantially cheaper class option.
Why is an SGLT2 inhibitor like Farxiga added when generic metformin is much cheaper?
Metformin is foundational first-line for T2DM and very cheap. SGLT2 inhibitors are added because the class has strong outcomes data beyond glucose lowering — reduced cardiovascular death, reduced heart failure hospitalization, and slowed CKD progression. Per ADA/EASD guidelines, SGLT2 inhibitors are preferred 2nd-line especially in patients with HF, CKD, or established ASCVD.
What is the difference between Farxiga, Jardiance, and Invokana?
All are SGLT2 inhibitors with overlapping benefits. Jardiance (empagliflozin) has the strongest CV mortality data (EMPA-REG, EMPEROR). Farxiga (dapagliflozin) has strong CKD data (DAPA-CKD, DAPA-HF) including in HFpEF (DELIVER) and post-MI. Invokana (canagliflozin) has HF and renal outcome data but carries an FDA labeling note for amputation risk from CANVAS. Choice often by insurance coverage and specific outcomes evidence. Brenzavvy is a cheaper class option with similar mechanism.
What is diabetic ketoacidosis (DKA) risk with Farxiga?
Euglycemic DKA (normal or only mildly elevated glucose) is possible with SGLT2 inhibitors. Risk factors: acute illness, surgery, fasting, very low carbohydrate diet, alcohol, T1DM (avoid). Hold Farxiga during sick days; stop 3–4 days before planned surgery. Recognize symptoms (nausea, vomiting, abdominal pain, malaise, rapid breathing) and check ketones with any concerning symptoms.
How does Farxiga affect my kidneys?
An initial small eGFR drop is expected and reversible — reflects normalization of glomerular hyperfiltration. Long-term Farxiga is renoprotective — slows CKD progression and reduces kidney failure. Recent guidance supports use down to eGFR 25 for cardiorenal protection.
Should I take Farxiga if I have heart failure even without diabetes?
Yes — Farxiga is FDA-approved for heart failure with reduced or preserved ejection fraction in adults regardless of diabetes status. Reduces cardiovascular death and HF hospitalization in addition to standard GDMT (ARNI, beta-blocker, MRA, diuretic as needed).
Why does Farxiga increase the risk of yeast infections?
Glucosuria (sugar in the urine) predisposes to genital yeast overgrowth — especially in women and in uncircumcised men. Educate on hygiene; topical antifungals usually treat episodes effectively without requiring Farxiga discontinuation. Recurrent severe infections may warrant switching class.
What happens if my Farxiga Patient Assistance Program application is denied?
We help explore Brenzavvy (much cheaper SGLT2 alternative), Mark Cuban Cost Plus, generic metformin foundation therapy, Jardiance copay programs (alternative SGLT2 with strong evidence), GLP-1 receptor agonist copay programs for diabetes and CV benefits, ARNI generic (Entresto generic emerging) for HF, ACE/ARB/beta-blocker/MRA foundational HF therapies, finerenone (Kerendia) for T2DM CKD, ADA/AADE resources, foundation aid (American Heart Association, National Kidney Foundation, Patient Access Network), and IRA negotiated Medicare pricing (effective 2026).
Take Control of Your Medication Costs
Diabetes, heart failure, and chronic kidney disease management should not be skipped over cost. SGLT2 inhibitors offer important cardiorenal benefits — and substantially cheaper alternatives are available. Our Farxiga advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Farxiga through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.